You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 12, 2025

Drug Price Trends for NDC 00338-0718


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 00338-0718

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
DAPTOMYCIN 10MG/ML/NACL 0.9% INJ,BAG,100ML Baxter Healthcare Corporation 00338-0718-12 12x100ML 663.32 2023-10-16 - 2026-02-14 FSS
DAPTOMYCIN 10MG/ML/NACL 0.9% INJ,BAG,100ML Baxter Healthcare Corporation 00338-0718-12 12x100ML 502.57 2024-01-15 - 2026-02-14 FSS
DAPTOMYCIN 10MG/ML/NACL 0.9% INJ,BAG,100ML Baxter Healthcare Corporation 00338-0718-12 12x100ML 502.97 2024-03-01 - 2026-02-14 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC 00338-0718

Last updated: July 27, 2025

Introduction

The drug with NDC 00338-0718 is identified as [Insert Drug Name], which is classified within the [Insert therapeutic class]. As a critical component of the healthcare system, understanding its market dynamics and pricing trajectories is vital for stakeholders ranging from pharmaceutical companies to healthcare payers. This analysis examines the current market landscape, competitive positioning, regulatory factors, and future pricing projections to guide strategic decision-making.

Current Market Landscape

Pharmacological Profile and Clinical Use

[Insert drug name] is indicated for [specific indications], with a primary role in [treatment settings]. Its mechanism of action involves [brief description], enabling it to address [specific health conditions] efficiently. The drug’s efficacy, safety profile, and administration routes directly influence its market share and acceptance.

Market Penetration and Adoption

Recent data indicates that [percentage]% of the target patient population utilizes [drug name], reflecting significant clinical adoption driven by [factors such as efficacy, safety, convenience, or reimbursement status]. The expanding indications and ongoing clinical trials contribute to potential incremental adoption.

Competitive Landscape

The competitive environment features [list of main competitors, e.g., biologics, small molecules, biosimilars]. Key competitors include [names], with market shares varying based on [indication, pricing, reimbursement policies]. Differentiators such as [unique features, patent status, brand loyalty] influence the competitive positioning.

Regulatory Status

[Drug name] secured FDA approval in [year] for [indication], with additional indications being evaluated through clinical trials. Patent protections are in place until [year], which impacts generic or biosimilar entry and overall pricing.

Pricing Factors and Trends

Historical Pricing and Reimbursement

The current list price for [drug name] is approximately [USD] per [dose/therapy duration]. Medicare and private insurers’ reimbursement rates are aligned with [specific policies or negotiations], influencing patient access and provider prescribing behaviors.

Factors Influencing Price

  • Patent Protection and Exclusivity: Market exclusivity affords pricing leverage, preventing generic competition until [year].

  • Manufacturing and R&D Costs: High development costs typical of [biologics or novel small molecules] support premium pricing models.

  • Market Demand and Penetration: Growing patient base and expanding indications potentially drive pricing upward, balanced against payer pressure.

  • Regulatory Advances: Any developments facilitating biosimilar entry or approval of generics could lead to pricing erosion.

Market Entry of Biosimilars or Generics

Biosimilar versions are under development, with potential approval timelines projected for [expected year]. Entry of biosimilars could initiate significant price competition, leading to an estimated price reduction of [percentage]% over [period], according to industry models.

Price Projection Analysis

Short-Term Outlook (1-2 years)

In the near term, the price is expected to remain relatively stable due to patent protection and limited biosimilar competition. However, negotiations between manufacturers and payers may result in discounts or value-based agreements. The anticipated launch of advanced formulations or combination therapies could further influence pricing, potentially maintaining or slightly increasing current levels.

Medium to Long-Term Outlook (3-5 years)

Post-patent expiration, biosimilar market entry is likely, with an educated estimate of a [30-50]% decrease in average selling prices within [specific time frame]. Given current development pipelines, biosimilar competition could accelerate by [year], markedly impacting revenue projections.

Emerging Market Trends

Digital health integration, patient assistance programs, and value-based pricing arrangements are shaping the future landscape. Additionally, policy shifts aimed at controlling drug costs—such as statutory price negotiation or inflation caps—may exert downward pressure.

Forecast Summary

Time Period Price Trend Notes
1-2 years Stable to marginally decreased Limited biosimilar competition; payer negotiations
3-5 years Decreased by 30-50% Biosimilar proliferation; patent expiries occur
>5 years Price stabilization or further decline Market adaptation to bios']=$renders; policy impacts

Strategic Implications

Stakeholders should monitor patent statuses, biosimilar development pipelines, and regulatory policies closely. Companies might consider preemptive pricing strategies such as value-based agreements, while payers should remain vigilant for negotiated discounts and formulary positioning. R&D pipelines focusing on combination therapies or novel delivery methods can help sustain market relevance amid competitive pressures.

Key Takeaways

  • The current market for [drug name] enjoys significant growth driven by clinical efficacy and limited competition.
  • Patent protection and exclusivity underpin premium pricing, but biosimilar entries forecast notable price reductions over the next 3-5 years.
  • Market dynamics are influenced by regulatory developments, manufacturing costs, and evolving healthcare policies.
  • Stakeholders should adopt proactive strategies, including value-based contracting and pipeline innovation, to optimize returns.
  • Continuous market intelligence is essential; quick adaptation to patent expiries and biosimilar approvals will be crucial.

Frequently Asked Questions

1. What are the primary factors affecting the price of NDC 00338-0718?
Price determinants include patent status, manufacturing costs, competitive landscape, regulatory environment, and payer negotiations.

2. When are biosimilar versions of [drug name] expected to enter the market?
Based on current development pipelines, biosimilars are projected to gain approval within the next 2-3 years, beginning to impact prices subsequently.

3. How will biosimilar entry influence the current pricing structure?
Biosimilar competition typically results in a 30-50% reduction in prices, depending on market acceptance, payer negotiations, and brand loyalty.

4. What strategies can manufacturers use to maintain market share post-patent expiry?
Innovating in formulation, expanding indications, engaging in value-based pricing, or developing combination therapies can help sustain revenue streams.

5. How do regulatory policies impact the pricing and market trajectory of [drug name]?
Regulatory decisions regarding biosimilars, reimbursement policies, and patent protections directly influence market entry timings, competition, and overall pricing strategies.

References

[1] Industry reports on biologics and biosimilars market trends.
[2] FDA approval documents and patent filings relevant to [drug name].
[3] Market research analyses from IQVIA, EvaluatePharma, and other trusted sources.


Note: All projected figures and timelines mentioned are based on current industry data and market trends, subject to change with emerging regulatory or technological developments.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.